NCT05194111

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 53 (estimated)
• Sponsor: Virginia Commonwealth University · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.

Detailed description

The current study will test the hypothesis that among adult age survivors of cancer diagnosed at age \< 39 years treatment of Stage B heart failure with sacubitril-valsartan is feasible and safe.

Conditions

• Heart Failure
• Heart Dysfunction

Interventions

Type	Name	Description
DRUG	Sacubitril-valsartan	Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
DRUG	Valsartan	Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)

Timeline

• Start date: 2022-08-11
• Primary completion: 2027-11-30
• Completion: 2028-11-30
• First posted: 2022-01-18
• Last updated: 2026-03-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study